Ocugen, Inc.
NASDAQ:OCGNBiotechnology
+$0.03 today
- Market cap
- $250.82M
- Beta
- 2.21
- P/E (TTM)
- -5.6
- EPS (TTM)
- -$0.22
Volume 5.83M
Average 7.51M
OCGN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Ocugen, Inc.NASDAQ: OCGN
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows in line with its trailing trend
Q1 FY2026 research & development of $11.26M rose 18.1% year over year, behind the +19.1% change in trailing-twelve-month research & development. Sequentially, it rose 5.5% from the prior quarter. Over 3 fiscal years it compounded at -10.9% a year.
Context
- Research & development amounted to 900.7% of revenue in FY2025, up 108.5 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +18.1% toward the trailing-twelve-month pace of +19.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 39.75M USD
- Year-over-year change
- +23.7%
- 4-year CAGR
- +3.2%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 39.75M | +23.7% |
| FY2024 | 2024-12-31 | 32.13M | -18.8% |
| FY2023 | 2023-12-31 | 39.57M | -29.5% |
| FY2022 | 2022-12-31 | 56.16M | +60.0% |
| FY2021 | 2021-12-31 | 35.11M | — |
Research & Development vs competitors
How OCGN compares with its peers on the latest reported figures
- OCGN's LTM Mar 2026 research & development of $41.48M is the 9th highest of the 10 companies compared; the peer median is $70.57M.
- Its year-over-year change of +19.1% is the 4th highest of 10, against a peer median of -8.7%.
- Research & development amounts to 928.9% of revenue for OCGN, versus a peer median of 127.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $346.63M | -8.7% | +56.3% | 4685.4% |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $162.51M | -21.6% | +18.9% | — |
| LTM Mar 2026 | $94.95M | -15.8% | -17.7% | 119.9% | |
| LTM Mar 2026 | $82.4M | +26.5% | +16.4% | — | |
| LTM Mar 2026 | $70.57M | -39.3% | -10.3% | 713.3% | |
| LTM Mar 2026 | $58.28M | -31.8% | +5.0% | 83.7% | |
| LTM Mar 2026 | $56.78M | +0.2% | -9.9% | — | |
| LTM Mar 2026 | $56.29M | +22.7% | +23.1% | — | |
| LTM Mar 2026 | $41.48M | +19.1% | -10.9% | 928.9% | |
| LTM Mar 2026 | $18.85M | +49.9% | +8.2% | 127.5% | |
| Peer median (excluding OCGN) | $70.57M | -8.7% | +8.2% | 127.5% | |
Competitors are the stored peer set for OCGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 2.49M | 6.04M | 4.06M | 4.41M |
| Cost of Revenue | 0 | 0 | 704K | 1.97M | 2.39M |
| Gross Profit | 0 | 2.49M | 5.33M | 2.09M | 2.02M |
| Gross Margin | — | 100.0% | 88.3% | 51.5% | 45.9% |
| Research & Development | 35.11M | 56.16M | 39.57M | 32.13M | 39.75M |
| Selling, General & Admin | 22.92M | 35.4M | 31.99M | 26.69M | 27.58M |
| Operating Expenses | 58.03M | 91.56M | 70.86M | 56.84M | 64.94M |
| Depreciation & Amortization | 229K | 480K | 704K | 1.97M | 2.39M |
| EBITDA | (58.11M) | (86.32M) | (62.37M) | (52.09M) | (60.27M) |
| EBITDA Margin | — | -3469.6% | -1033.4% | -1284.5% | -1365.7% |
| Operating Income | (58.03M) | (89.07M) | (65.53M) | (54.76M) | (62.92M) |
| Operating Margin | — | -3580.0% | -1085.7% | -1350.4% | -1425.7% |
| Interest Income | 0 | 1.4M | 2.5M | 1.3M | 922K |
| Interest Expense | 79K | 0 | 0 | 0 | 5.19M |
| Other Income / Expenses | (389K) | 2.27M | 2.45M | 703K | (4.93M) |
| Income Before Tax | (58.42M) | (86.8M) | (63.08M) | (54.05M) | (67.85M) |
| Pre-Tax Margin | — | -3488.9% | -1045.0% | -1333.0% | -1537.4% |
| Income Tax Expense | (52K) | 0 | 0 | 0 | 0 |
| Net Income | (58.37M) | (86.8M) | (63.08M) | (54.05M) | (67.85M) |
| Net Margin | — | -3488.9% | -1045.0% | -1333.0% | -1537.4% |
| EPS (Basic) | (0.30) | (0.40) | (0.26) | (0.20) | (0.23) |
| EPS (Diluted) | (0.30) | (0.40) | (0.26) | (0.20) | (0.23) |
| Weighted Avg Shares | 195.01M | 214.6M | 244.33M | 271M | 300.17M |
| Weighted Avg Shares (Diluted) | 195.01M | 214.6M | 244.33M | 271M | 300.17M |
Ocugen, Inc.
NASDAQ:OCGN
Intrinsic Alpha fair value
Locked
Current Price
$0.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.